Ocular Therapeutix, Inc. (OCUL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ocular Therapeutix, Inc. (OCUL) closed at USD 7.20 on 2026-10-14, a change of -37.6 % over the past year, with a market capitalization of USD 1.62B.

Ocular Therapeutix, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ocular Therapeutix, Inc. key figures

Previous close

USD 7.20 (2026-10-14)

1-year change

-37.6 %

Market cap

USD 1.62B

Enterprise value

USD 1.1B

P/E ratio (trailing)

-5.16

P/E ratio (forward)

-4.99

EPS (trailing)

-1.43

EPS (forward)

-1.48

PEG ratio

n/a

Price to book

3.12

Revenue growth

0.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.49

Employees

325

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ocular Therapeutix, Inc. and compare it with other stocks.